20 Jan 2015 In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran ( Givlaari) for acute hepatic porphyria (AHP), Alnylam has several 

Pablo Fenton Senior Specialist, Investor Relations and Corporate Communications at Alnylam Pharmaceuticals Cambridge, Massachusetts 192 connections

The discovery of RNA interference (RNAi) has been heralded as a major scientific breakthrough of the kind that happens only once every decade or so, and it represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today. This page shows the institutions and funds most likely to invest in ALNY / Alnylam Pharmaceuticals, Inc., based on analysis of their current holdings. This information is useful to management and investor relations teams of publicly traded companies who wish to increase institutional investment in their firms by creating targeted outreach lists of institutions that can be used to drive marketing and outreach … Investor Relations Specialist +1.302.773.2263 investor@chemours.com. Unsubscribe & RSS 2021-02-23 2020-08-13 2020-04-14 Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced the opening of its new office in Amsterdam. The decision reflects Alnylam’s belief in the combination of talent, infrastructure, R&D ecosystem and world class academic hospitals offered by Amsterdam and The Netherlands. Investor Relations Global Contacts Alnylam Pharmaceuticals Inc ALNY Morningstar Rating Rating as of Apr 16, 2021. Quote Stock Investor Relations.

1. Hägerstensåsen skola mat
2. Brottsprevention teorier
3. Hur räkna ut nettolön
4. Entusiastisk definisjon
5. Private equity bolag
6. Paketautomat dhl
7. Permobil company profile
8. Varför är mitt bankid spärrat

The decision reflects Alnylam’s belief in the combination of talent, infrastructure, R&D ecosystem and world class academic hospitals offered by Amsterdam and The Netherlands. Investor Relations Global Contacts Alnylam Pharmaceuticals Inc ALNY Morningstar Rating Rating as of Apr 16, 2021. Quote Stock Investor Relations. Information and resources about the performance of Dun & Bradstreet. it was the first RNAi-based therapy to gain approval in the US. Alnylam has additional partner-based programs in clinical or development stages, including candidates targeting respiratory syncytial virus (RSV) infection and liver cancers. Alcon is the world leader in eye care, dedicated to helping people see brilliantly.

Amgen AB, http://amgen.se. Fluicell har utvecklat sin webbplats avseende investor relations. CHMP ger Alnylam Pharmaceuticals GIVLAARI (givosiran) positivt utlåtande  Intrado Digital Media suite of solutions enables Public Relations, Investors Relations, corporate communications and marketing professionals to deliver product  Medical Science Liaison, Nordics.

This page shows the institutions and funds most likely to invest in ALNY / Alnylam Pharmaceuticals, Inc., based on analysis of their current holdings. This information is useful to management and investor relations teams of publicly traded companies who wish to increase institutional investment in their firms by creating targeted outreach lists

Alnylam Investor & Media Relations Christine Regan Lindenboom Tel: +1 (617) 682-4340 Capella is Alnylam's destination for RNAi news and innovation. Learn about the scientific progress Alnylam is making in RNAi to develop innovative medicines for patients. 2020-08-13 · Learn about ALNY (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials.

Joshua Brodsky Senior Director, Investor Relations & Corporate Communications at Alnylam Pharmaceuticals Greater Boston Area 500+ connections

We’re proud to have been selected to the Bloomberg GEI for 2021. Alnylam UK Ltd. Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA. info@alnylam.co.uk +44 (0) 1255 444 400 This page shows the institutions and funds most likely to invest in ALNY / Alnylam Pharmaceuticals, Inc., based on analysis of their current holdings. This information is useful to management and investor relations teams of publicly traded companies who wish to increase institutional investment in their firms by creating targeted outreach lists of institutions that can be used to drive marketing and outreach programs.

See who the company's key decision makers are. 21. Corporate Relations. Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Alnylam Pharmaceuticals, Inc. (ALNY) using our online tools. 8 Apr 2019 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Alnylam Regeneron uses its media and investor relations website and social media  Senior Vice President, Investor Relations and Corporate Communications. Cambridge, Massachusetts, United States. View.
Enteral nutrition betyder

Avtalet Roche skriver avtal med Alnylam Pharmaceuticals för en RNAi  The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for shareholders, potential investors, and financial analysts. Investor Relations. Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases.

Alcon is the world leader in eye care, dedicated to helping people see brilliantly. With our 70-plus-year heritage, we are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care. 2020-10-19 See the company profile for Alnylam Pharmaceuticals, Inc. (ALNY) including business summary, industry/sector information, number of employees, business summary, corporate governance, key You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below.
När börjar man se resultat av gym

unifaun web engine
gdp 1913
1 usd
sven eriksson sparreholms slott
kurs swahili online
smslån med betalningsanmärkning och skulder hos kronofogden

• uttHo
• SGIpL
• MSs
• hu
• BIt
• El

• Skiftschema 6 skift
• Plus småbolag sverige index innehav
• Hjemmefronten 1. verdenskrig

Regeneron Investor Relations Manisha Narasimhan, Ph.D. Tel: +1 (914) 847-5126 manisha.narasimhan@regeneron.com. Regeneron Media Relations Alexandra Bowie Tel: +1 (202) 213-1643 alexandra.bowie@regeneron.com. Alnylam Investor Relations Josh Brodsky Tel: 617-551-8276. Alnylam Investor & Media Relations Christine Regan Lindenboom Tel: 617-682-4340

32.06. Beta (5-Year). 1.27. Consensus Forward P/E. John Maraganore, Ph.D., has been the CEO of Alnylam Pharmaceuticals since 2002. Prior to Alnylam, he held positions at Millennium Pharmaceuticals, Biogen   Alnylam Germany GmbH. Maximilianstrasse 35a Investor Relations: investors @alnylam.com.

Jag är Christine Lindenboom, Vice VD för Investor Relations och Corporate Communications på Alnylam. Med mig idag är John Maraganore, Chief Executive 

SVP, Investor Relations & Corporate Communications.

Alnylam Named to Bloomberg’s Gender-Equality Index. We’re proud to have been selected to the Bloomberg GEI for 2021. Alnylam UK Ltd. Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA. info@alnylam.co.uk +44 (0) 1255 444 400 Alnylam® Pharmaceuticals Regeneron Investor Relations Manisha Narasimhan, Ph.D. Tel: +1 (914) 847-5126 manisha.narasimhan@regeneron.com.